U.S. markets close in 3 hours 21 minutes
  • S&P 500

    3,939.04
    -18.59 (-0.47%)
     
  • Dow 30

    33,589.80
    -262.73 (-0.78%)
     
  • Nasdaq

    10,973.34
    -10.44 (-0.10%)
     
  • Russell 2000

    1,822.80
    -13.76 (-0.75%)
     
  • Crude Oil

    80.42
    +2.22 (+2.84%)
     
  • Gold

    1,767.80
    +4.10 (+0.23%)
     
  • Silver

    21.84
    +0.40 (+1.88%)
     
  • EUR/USD

    1.0311
    -0.0023 (-0.23%)
     
  • 10-Yr Bond

    3.7720
    +0.0240 (+0.64%)
     
  • GBP/USD

    1.1929
    -0.0021 (-0.18%)
     
  • USD/JPY

    139.4160
    +0.7820 (+0.56%)
     
  • BTC-USD

    16,782.11
    +397.56 (+2.43%)
     
  • CMC Crypto 200

    398.40
    -2.29 (-0.57%)
     
  • FTSE 100

    7,573.05
    +61.05 (+0.81%)
     
  • Nikkei 225

    27,968.99
    -58.85 (-0.21%)
     

Akebia Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 4, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 4:30 p.m. ET.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)

An audio replay of the presentation will be available through the Investors section of Akebia's website at https://ir.akebia.com for approximately 30 days following the conference.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
Mcarrasco@akebia.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-40th-annual-jp-morgan-healthcare-conference-301452956.html

SOURCE Akebia Therapeutics